Dirk Blondin
Dirk Blondin has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Gerald Antoch
Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, 40225 Dusseldorf, Germany
7 shared publications - Lars Schimmöller
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, Dusseldorf, Germany; Department of Diagnostic, Interventional Radiology and Nuclear Medicine, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany
7 shared publications - Peter Albers
Department of Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
7 shared publications - Andreas Hiester
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
5 shared publications - Robert Rabenalt
Department of Urology, University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Düsseldorf, Germany
5 shared publications - Christian Arsov
University Dusseldorf, Medical Faculty, Department of Urology, D-40225 Dusseldorf, Germany
4 shared publications
Latest Publications
- 13 September 2022
- Published by Elsevier in European Journal of Radiology
- Vol. 156, 110520
Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection
- 13 September 2022
- Published by Elsevier in European Journal of Radiology
- Vol. 156, 110520
Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection
- 1 April 2019
- Published by Elsevier in European Journal of Radiology
- Vol. 113, 1-6
Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients
- 1 April 2019
- Published by Elsevier in European Journal of Radiology
- Vol. 113, 1-6
Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients
- 1 May 2017
- Published by Elsevier in European Journal of Radiology
- Vol. 90, 192-197
Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: A prospective comparison study of image quality
- 1 May 2017
- Published by Elsevier in European Journal of Radiology
- Vol. 90, 192-197
Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: A prospective comparison study of image quality
- 19 December 2016
- Published by Georg Thieme Verlag KG in Radiopraxis
- Vol. 9 (04) , 189-200
Fetale MRT
Die fetale MRT ist eine seltene Spezialuntersuchung, die in Deutschland nur in wenigen Kliniken bzw. Praxen angeboten wird. Die Indikation zu dieser MRT-Untersuchung wird durch Pränatalmediziner oder Gynäkologen mit einer entsprechenden Qualifikation im pränatalen Ultraschall – Ausbildungsstatus DEGUM 2 oder 3 – gestellt. Erst durch die Entwicklung schneller Sequenztechniken wurde eine suffiziente Bildgebung des Fetus im MRT möglich. Zur Beurteilung eines fetalen MRT bedarf es von radiologischer Seite einer entsprechenden Erfahrung, die nur an wenigen Ausbildungsstätten erworben werden kann. Die fetale MRT wird der Kinderradiologie zugeordnet, aber auch Neuroradiologen, die Kinder und Jugendliche mit angeborenen Malformationen oder Syndromen betreuen, bieten die fetale MRT an. Der Artikel soll keine Übersichtsarbeit über die häufigsten Indikationen oder Befunde darstellen, aber anhand von Befund- bzw. Bildbeispielen soll ein Eindruck über die vielen verschiedenen Erkrankungen vermittelt werden. Darüber hinaus werden wichtige Hinweise zur Anfertigung eines fetalen MRT dargelegt. The fetal MRI is a rare and special examination, available only at a few clinics or practices throughout Germany. Prenatal doctors or gynecologists indicate the MRI examination by a prenatal ultrasonic – DEGUM education level 2 or 3. Only the development of fast sequential MRI allows for sufficient imaging of the fetus. Although the fetal MRI is assigned to pediatric radiology, it is also used in neuroradiology for the treatment of children and adolescents with congenital malformations or syndromes. This article does not claim to survey the most common indications, but should give an impression of the various diseases by the means of examples of indications and images. Furthermore, important hints at fetal MRI are given.
- 19 December 2016
- Published by Georg Thieme Verlag KG in Radiopraxis
- Vol. 9 (04) , 189-200
Fetale MRT
Die fetale MRT ist eine seltene Spezialuntersuchung, die in Deutschland nur in wenigen Kliniken bzw. Praxen angeboten wird. Die Indikation zu dieser MRT-Untersuchung wird durch Pränatalmediziner oder Gynäkologen mit einer entsprechenden Qualifikation im pränatalen Ultraschall – Ausbildungsstatus DEGUM 2 oder 3 – gestellt. Erst durch die Entwicklung schneller Sequenztechniken wurde eine suffiziente Bildgebung des Fetus im MRT möglich. Zur Beurteilung eines fetalen MRT bedarf es von radiologischer Seite einer entsprechenden Erfahrung, die nur an wenigen Ausbildungsstätten erworben werden kann. Die fetale MRT wird der Kinderradiologie zugeordnet, aber auch Neuroradiologen, die Kinder und Jugendliche mit angeborenen Malformationen oder Syndromen betreuen, bieten die fetale MRT an. Der Artikel soll keine Übersichtsarbeit über die häufigsten Indikationen oder Befunde darstellen, aber anhand von Befund- bzw. Bildbeispielen soll ein Eindruck über die vielen verschiedenen Erkrankungen vermittelt werden. Darüber hinaus werden wichtige Hinweise zur Anfertigung eines fetalen MRT dargelegt. The fetal MRI is a rare and special examination, available only at a few clinics or practices throughout Germany. Prenatal doctors or gynecologists indicate the MRI examination by a prenatal ultrasonic – DEGUM education level 2 or 3. Only the development of fast sequential MRI allows for sufficient imaging of the fetus. Although the fetal MRI is assigned to pediatric radiology, it is also used in neuroradiology for the treatment of children and adolescents with congenital malformations or syndromes. This article does not claim to survey the most common indications, but should give an impression of the various diseases by the means of examples of indications and images. Furthermore, important hints at fetal MRI are given.
- 26 February 2016
- Published by Springer Nature in European Radiology
- Vol. 26 (11) , 3858-3864
Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
Purpose This study evaluates the feasibility of performing less than two core biopsies per MRI-lesion when performing targeted MR-guided in-bore prostate biopsy. Methods Retrospectively evaluated were 1545 biopsy cores of 774 intraprostatic lesions (two cores per lesion) in 290 patients (66 ± 7.8 years; median PSA 8.2 ng/ml) regarding prostate cancer (PCa) detection, Gleason score, and tumor infiltration of the first (FBC) compared to the second biopsy core (SBC). Biopsies were acquired under in-bore MR-guidance. Results For the biopsy cores, 491 were PCa positive, 239 of 774 (31 %) were FBC and 252 of 771 (33 %) were SBC (p = 0.4). Patient PCa detection rate based on the FBC vs. SBC were 46 % vs. 48 % (p = 0.6). For clinically significant PCa (Gleason score ≥4 + 3 = 7) the detection rate was 18 % for both, FBC and SBC (p = 0.9). Six hundred and eighty-seven SBC (89 %) showed no histologic difference. On the lesion level, 40 SBC detected PCa with negative FBC (7.5 %). Twenty SBC showed a Gleason upgrade from 3 + 3 = 6 to ≥3 + 4 = 7 (2.6 %) and 4 to ≥4 + 3 = 7 (0.5 %). Conclusion The benefit of a second targeted biopsy core per suspicious MRI-lesion is likely minor, especially regarding PCa detection rate and significant Gleason upgrading. Therefore, a further reduction of biopsy cores is reasonable when performing a targeted MR-guided in-bore prostate biopsy. Key Points • Higher PI-RADS overall score (IV-V) correlated well with PCa detection rate • In more than 80 % SBC was concordant regarding overall PCa detection • In almost 90 % there was no Gleason upgrading by the SBC • Only 2/54 (3.7 %) csPCa was missed when the SBC was omitted • For IB-GB a further reduction of biopsy cores is reasonable
- 26 February 2016
- Published by Springer Nature in European Radiology
- Vol. 26 (11) , 3858-3864
Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
Purpose This study evaluates the feasibility of performing less than two core biopsies per MRI-lesion when performing targeted MR-guided in-bore prostate biopsy. Methods Retrospectively evaluated were 1545 biopsy cores of 774 intraprostatic lesions (two cores per lesion) in 290 patients (66 ± 7.8 years; median PSA 8.2 ng/ml) regarding prostate cancer (PCa) detection, Gleason score, and tumor infiltration of the first (FBC) compared to the second biopsy core (SBC). Biopsies were acquired under in-bore MR-guidance. Results For the biopsy cores, 491 were PCa positive, 239 of 774 (31 %) were FBC and 252 of 771 (33 %) were SBC (p = 0.4). Patient PCa detection rate based on the FBC vs. SBC were 46 % vs. 48 % (p = 0.6). For clinically significant PCa (Gleason score ≥4 + 3 = 7) the detection rate was 18 % for both, FBC and SBC (p = 0.9). Six hundred and eighty-seven SBC (89 %) showed no histologic difference. On the lesion level, 40 SBC detected PCa with negative FBC (7.5 %). Twenty SBC showed a Gleason upgrade from 3 + 3 = 6 to ≥3 + 4 = 7 (2.6 %) and 4 to ≥4 + 3 = 7 (0.5 %). Conclusion The benefit of a second targeted biopsy core per suspicious MRI-lesion is likely minor, especially regarding PCa detection rate and significant Gleason upgrading. Therefore, a further reduction of biopsy cores is reasonable when performing a targeted MR-guided in-bore prostate biopsy. Key Points • Higher PI-RADS overall score (IV-V) correlated well with PCa detection rate • In more than 80 % SBC was concordant regarding overall PCa detection • In almost 90 % there was no Gleason upgrading by the SBC • Only 2/54 (3.7 %) csPCa was missed when the SBC was omitted • For IB-GB a further reduction of biopsy cores is reasonable
- 9 June 2015
- Published by Springer Nature in World Journal of Urology
- Vol. 34 (2) , 215-220
Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial
The objective of this study was to compare patient comfort between MR-guided in-bore prostate biopsy (IB-GB) and MRI/ultrasound fusion-guided prostate biopsy (FUS-GB) with additional systematic 12-core transrectal ultrasound (TRUS)-guided biopsy within a prospective randomized trial. Two hundred and ten consecutive patients were randomly assigned in a 1:1 ratio to receive either IB-GB and prior intrarectal instillation of a 2 % lidocaine gel (n = 106) or FUS-GB plus additional systematic 12-core TRUS-guided biopsy and prior application of a periprostatic nerve block (PPNB) with 2 % mepivacaine (n = 104). The maximal procedural pain (MPP) on a 0–10 visual analog scale and the operating room time were recorded for each biopsy session. Baseline characteristics and mean number of targeted biopsy cores (5.6 ± 0.8 vs 5.4 ± 1.2 for IB-GB and FUS-GB, respectively; p = 0.278) were similar in both study arms. In relation to the IB-GB arm, the total number of biopsy cores in the FUS-GB arm, including the systematic 12-core TRUS-guided biopsy, was significantly higher (17.4 ± 1.2; p < 0.001). Patients with IB-GB had significantly higher MPP scores (2.95 ± 2.15) compared with subjects with FUS-GB (1.95 ± 1.56; p < 0.001). FUS-GB required significantly less time (28.22 ± 11.61 min) in comparison with IB-GB (42.09 ± 11.37 min; p < 0.001). The PPNB can easily be administered just prior to performing FUS-GB. Thus, patients have significantly lower pain levels in comparison with IB-GB, which is usually done with intrarectal anesthetic gels. Although the addition of a systematic 12-core TRUS-guided biopsy significantly increases the number of biopsy cores, FUS-GB still requires significantly less time in comparison with IB-GB.
- 9 June 2015
- Published by Springer Nature in World Journal of Urology
- Vol. 34 (2) , 215-220
Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial
The objective of this study was to compare patient comfort between MR-guided in-bore prostate biopsy (IB-GB) and MRI/ultrasound fusion-guided prostate biopsy (FUS-GB) with additional systematic 12-core transrectal ultrasound (TRUS)-guided biopsy within a prospective randomized trial. Two hundred and ten consecutive patients were randomly assigned in a 1:1 ratio to receive either IB-GB and prior intrarectal instillation of a 2 % lidocaine gel (n = 106) or FUS-GB plus additional systematic 12-core TRUS-guided biopsy and prior application of a periprostatic nerve block (PPNB) with 2 % mepivacaine (n = 104). The maximal procedural pain (MPP) on a 0–10 visual analog scale and the operating room time were recorded for each biopsy session. Baseline characteristics and mean number of targeted biopsy cores (5.6 ± 0.8 vs 5.4 ± 1.2 for IB-GB and FUS-GB, respectively; p = 0.278) were similar in both study arms. In relation to the IB-GB arm, the total number of biopsy cores in the FUS-GB arm, including the systematic 12-core TRUS-guided biopsy, was significantly higher (17.4 ± 1.2; p < 0.001). Patients with IB-GB had significantly higher MPP scores (2.95 ± 2.15) compared with subjects with FUS-GB (1.95 ± 1.56; p < 0.001). FUS-GB required significantly less time (28.22 ± 11.61 min) in comparison with IB-GB (42.09 ± 11.37 min; p < 0.001). The PPNB can easily be administered just prior to performing FUS-GB. Thus, patients have significantly lower pain levels in comparison with IB-GB, which is usually done with intrarectal anesthetic gels. Although the addition of a systematic 12-core TRUS-guided biopsy significantly increases the number of biopsy cores, FUS-GB still requires significantly less time in comparison with IB-GB.
- 1 December 2014
- Published by Elsevier in European Journal of Radiology
- Vol. 83 (12) , 2103-2108
Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy
- 1 December 2014
- Published by Elsevier in European Journal of Radiology
- Vol. 83 (12) , 2103-2108
Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy
- 28 June 2014
- Published by Springer Nature in European Radiology
- Vol. 24 (10) , 2582-2589
MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy
This study evaluated the accuracy of MR sequences [T2-, diffusion-weighted, and dynamic contrast-enhanced (T2WI, DWI, and DCE) imaging] at 3T, based on the European Society of Urogenital Radiology (ESUR) scoring system [Prostate Imaging Reporting and Data System (PI-RADS)] using MR-guided in-bore prostate biopsies as reference standard. In 235 consecutive patients [aged 65.7 ± 7.9 years; median prostate-specific antigen (PSA) 8 ng/ml] with multiparametric prostate MRI (mp-MRI), 566 lesions were scored according to PI-RADS. Histology of all lesions was obtained by targeted MR-guided in-bore biopsy. In 200 lesions, biopsy revealed prostate cancer (PCa). The area under the curve (AUC) for cancer detection was 0.70 (T2WI), 0.80 (DWI), and 0.74 (DCE). A combination of T2WI + DWI, T2WI + DCE, and DWI + DCE achieved an AUC of 0.81, 0.78, and 0.79. A summed PI-RADS score of T2WI + DWI + DCE achieved an AUC of 0.81. For higher grade PCa (primary Gleason pattern ≥ 4), the AUC was 0.85 for T2WI + DWI, 0.84 for T2WI + DCE, 0.86 for DWI + DCE, and 0.87 for T2WI + DWI + DCE. The AUC for T2WI + DWI + DCE for transitional-zone PCa was 0.73, and for the peripheral zone 0.88. Regarding higher-grade PCa, AUC for transitional-zone PCa was 0.88, and for peripheral zone 0.96. The combination of T2WI + DWI + DCE achieved the highest test accuracy, especially in patients with higher-grade PCa. The use of ≤2 MR sequences led to lower AUC in higher-grade and peripheral-zone cancers. • T2WI + DWI + DCE achieved the highest accuracy in patients with higher grade PCa • T2WI + DWI + DCE was more accurate for peripheral- than for transitional-zone PCa • DCE increased PCa detection accuracy in the peripheral zone • DWI was the leading sequence in the transitional zone
- 28 June 2014
- Published by Springer Nature in European Radiology
- Vol. 24 (10) , 2582-2589
MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy
This study evaluated the accuracy of MR sequences [T2-, diffusion-weighted, and dynamic contrast-enhanced (T2WI, DWI, and DCE) imaging] at 3T, based on the European Society of Urogenital Radiology (ESUR) scoring system [Prostate Imaging Reporting and Data System (PI-RADS)] using MR-guided in-bore prostate biopsies as reference standard. In 235 consecutive patients [aged 65.7 ± 7.9 years; median prostate-specific antigen (PSA) 8 ng/ml] with multiparametric prostate MRI (mp-MRI), 566 lesions were scored according to PI-RADS. Histology of all lesions was obtained by targeted MR-guided in-bore biopsy. In 200 lesions, biopsy revealed prostate cancer (PCa). The area under the curve (AUC) for cancer detection was 0.70 (T2WI), 0.80 (DWI), and 0.74 (DCE). A combination of T2WI + DWI, T2WI + DCE, and DWI + DCE achieved an AUC of 0.81, 0.78, and 0.79. A summed PI-RADS score of T2WI + DWI + DCE achieved an AUC of 0.81. For higher grade PCa (primary Gleason pattern ≥ 4), the AUC was 0.85 for T2WI + DWI, 0.84 for T2WI + DCE, 0.86 for DWI + DCE, and 0.87 for T2WI + DWI + DCE. The AUC for T2WI + DWI + DCE for transitional-zone PCa was 0.73, and for the peripheral zone 0.88. Regarding higher-grade PCa, AUC for transitional-zone PCa was 0.88, and for peripheral zone 0.96. The combination of T2WI + DWI + DCE achieved the highest test accuracy, especially in patients with higher-grade PCa. The use of ≤2 MR sequences led to lower AUC in higher-grade and peripheral-zone cancers. • T2WI + DWI + DCE achieved the highest accuracy in patients with higher grade PCa • T2WI + DWI + DCE was more accurate for peripheral- than for transitional-zone PCa • DCE increased PCa detection accuracy in the peripheral zone • DWI was the leading sequence in the transitional zone